FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved BPC 157: The Real Reason Why It's Not FDA Approved Stracuzzi Wellness The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York